PA
MRNA icon

Probity Advisors’s Moderna MRNA Stock Holding History

Probity Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$627K Sell
8,947
-197
-2% -$10.2K 0.09% 141
2026
Q1 		$465K Sell
9,144
-535
-6% -$25K 0.07% 167
2025
Q4 		$285K Sell
9,679
-3,265
-25% -$88.7K 0.05% 207
2025
Q3 		$334K Sell
12,944
-1,948
-13% -$54.3K 0.05% 190
2025
Q2 		$411K Buy
14,892
+377
+3% +$9.93K 0.07% 165
2025
Q1 		$412K Buy
14,515
+3,769
+35% +$134K 0.08% 165
2024
Q4 		$447K Buy
10,746
+5,902
+122% +$282K 0.09% 155
2024
Q3 		$324K Buy
4,844
+661
+16% +$60.7K 0.06% 189
2024
Q2 		$497K Buy
4,183
+774
+23% +$97.9K 0.1% 144
2024
Q1 		$363K Buy
+3,409
New +$344K 0.08% 172

Other funds holding MRNA

BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Probity Advisors's MRNA Position: Q2 2026 in Review

Probity Advisors reduced its Moderna (MRNA) stake by 2.2% in Q2 2026, selling an estimated $10.2K and leaving 8,947 shares worth $627K. The position accounts for 0.09% of the portfolio, ranked #141.

Probity Advisors first reported a position in MRNA in Q1 2024 and has held it in 10 quarters since. 314 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Probity Advisors held 8,947 shares of Moderna worth $627K as of Q2 2026.
  • Probity Advisors sold 197 Moderna shares in Q2 2026, an estimated $10.2K.
  • Moderna made up 0.09% of Probity Advisors's portfolio in Q2 2026, its #141 holding.
  • Probity Advisors first reported a position in Moderna in Q1 2024 and has held it in 10 quarters since.
  • 314 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.